Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 20Other hematologic neoplasm 5Gynecologic 3Genitourinary 3Gastrointestinal 3Breast 3Head & Neck 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Plasma cell 1Myeloid 1Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 416Radiotherapy 240Radiotherapy, Intensity-Modulated 178Cetuximab 177Docetaxel 166pembrolizumab 148Carboplatin 121Fluorouracil 113Paclitaxel 90Nivolumab 82Gemcitabine 82Radiation 72Surveys and Questionnaires 71Drug Therapy 70toripalimab 68Surgical Procedures, Operative 64Magnetic Resonance Spectroscopy 63Capecitabine 50Blood Specimen Collection 50Chemoradiotherapy 46Biopsy 44camrelizumab 41durvalumab 40Radiosurgery 40Standard of Care 38Erlotinib Hydrochloride 34nimotuzumab 32130-nm albumin-bound paclitaxel 32tislelizumab 31apatinib 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × copanlisib × Head & Neck × Clear all
NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
8 enrolled 8 charts
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT02822482 2021-03-29

COPAN-ORL06

UNICANCER

Phase 1/2 Terminated
11 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡